These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16102553)

  • 1. Randomized assignment to copper IUD or depot-medroxyprogesterone acetate: feasibility of enrollment, continuation and disease ascertainment.
    Feldblum PJ; Caraway J; Bahamondes L; El-Shafei M; Quan Ha D; Morales E; Wevill S; Condon S
    Contraception; 2005 Sep; 72(3):187-91. PubMed ID: 16102553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
    Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.
    Picardo C; Ferreri S
    Contraception; 2010 Aug; 82(2):160-7. PubMed ID: 20654757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant.
    Deese J; Philip N; Lind M; Ahmed K; Batting J; Beksinska M; Edward VA; Louw CE; Onono M; Palanee-Phillips T; Smit JA; Baeten JM; Donnell D; Mastro TD; Mugo NR; Nanda K; Rees H; Morrison C
    Sex Transm Infect; 2021 Jun; 97(4):249-255. PubMed ID: 33208512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A reanalysis of the Cu-7 intrauterine contraceptive device clinical trial and the incidence of pelvic inflammatory disease: a paradigm for assessing intrauterine contraceptive device safety.
    Roy S; Azen C
    Am J Obstet Gynecol; 1994 Jun; 170(6):1606-13; discussion 1613-6. PubMed ID: 8203417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body weight and body composition of depot medroxyprogesterone acetate users.
    Dal'Ava N; Bahamondes L; Bahamondes MV; Bottura BF; Monteiro I
    Contraception; 2014 Aug; 90(2):182-7. PubMed ID: 24780631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal contraception and the risks of STI acquisition: results of a feasibility study to plan a future randomized trial.
    Hubacher D; Raymond ER; Beksinska M; Delany-Moretlwe S; Smit J; Hylton-Kong T; Moench TR
    Contraception; 2008 May; 77(5):366-70. PubMed ID: 18402854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate.
    Sanches L; Marchi NM; Castro S; Juliato CT; Villarroel M; Bahamondes L
    Contraception; 2008 Nov; 78(5):365-9. PubMed ID: 18929732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An introductory clinical trial of three-monthly injectable contraceptive-depot medroxyprogesterone acetate].
    Shao Q; Jiang H; Fu W
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jan; 34(1):36-9. PubMed ID: 11263172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depo Now: preventing unintended pregnancies among adolescents and young adults.
    Rickert VI; Tiezzi L; Lipshutz J; León J; Vaughan RD; Westhoff C
    J Adolesc Health; 2007 Jan; 40(1):22-8. PubMed ID: 17185202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.
    Prabhakaran S; Sweet A
    Contraception; 2012 May; 85(5):453-7. PubMed ID: 22079605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immediate monthly combination contraception to facilitate initiation of the depot medroxyprogesterone acetate contraceptive injection.
    Morroni C; Grams M; Tiezzi L; Westhoff C
    Contraception; 2004 Jul; 70(1):19-23. PubMed ID: 15208048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuation rates among injectable contraceptive users.
    Westfall JM; Main DS; Barnard L
    Fam Plann Perspect; 1996; 28(6):275-7. PubMed ID: 8959418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age.
    Bahamondes L; Faundes A; Sobreira-Lima B; Lui-Filho JF; Pecci P; Matera S
    Contraception; 2005 Nov; 72(5):337-41. PubMed ID: 16246658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of depot medroxyprogesterone acetate on the day of mifepristone for medical abortion: a pilot study.
    Sonalkar S; McClusky J; Hou MY; Borgatta L
    Contraception; 2015 Feb; 91(2):174-7. PubMed ID: 25481376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pelvic inflammatory disease attributable to the IUD: modeling risk in West Africa.
    Stanback J; Shelton JD
    Contraception; 2008 Apr; 77(4):227-9. PubMed ID: 18342643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.
    Beasley A; White KO; Cremers S; Westhoff C
    Contraception; 2014 May; 89(5):352-6. PubMed ID: 24656555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrauterine devices: an effective alternative to oral hormonal contraception.
    Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up visits after IUD insertion. Are more better?
    Hubacher D; Fortney J
    J Reprod Med; 1999 Sep; 44(9):801-6. PubMed ID: 10509305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Randomized comparative study of GyneFix IN and TCu 380A intrauterine devices].
    Wu S; Hu J; Wu M
    Zhonghua Fu Chan Ke Za Zhi; 1998 Jun; 33(6):345-8. PubMed ID: 10806672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.